Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study
Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patients with CD.
Authors
- Serena Yun‐Chen Tsai (ORCID: https://orcid.org/0000-0002-5778-645X)
- Ashwin N. Ananthakrishnan (ORCID: https://orcid.org/0000-0002-9436-1821)
- Kevin Sheng‐Kai (ORCID: https://orcid.org/0000-0002-9394-4144)
- Harland S. Winter (ORCID: https://orcid.org/0000-0002-3202-7772)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- Center for Global Health (US)
- Center for Pain and the Brain (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Pediatric Drugs
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s40272-025-00717-2
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- National Institutes of Health